Date	Price Target	Rating	Analyst
7/25/2025	$18.00	Neutral	Goldman
12/30/2024	$19.00	Buy	H.C. Wainwright
8/28/2024	$15.00	Buy	Jefferies
1/3/2024	$4.00 → $8.00	Neutral → Buy	Mizuho
10/26/2023	$57.00 → $4.00	Buy → Neutral	Mizuho
10/13/2023	$32.00 → $6.00	Buy → Neutral	Goldman
9/7/2022	$46.00	Buy	Needham
3/17/2022	$45.00	Buy	Goldman

More analyst ratings

FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

12/15/23 5:01:31 PM ET

$ARQT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ARQT alert in real time by email

New Drug Application (NDA): 217242
Company: ARCUTIS BIOTHERAPEUTICS INC

Products on NDA 217242

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
ZORYVE	ROFLUMILAST	0.3%	FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for NDA 217242

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
12/15/2023	ORIG-1	Approval	Type 3 - New Dosage Form and Type 4 - New Combination	STANDARD		Label is not available on this site.

Get the next $ARQT alert in real time by email

Crush Q3 2025 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$ARQT

Date	Price Target	Rating	Analyst
7/25/2025	$18.00	Neutral	Goldman
12/30/2024	$19.00	Buy	H.C. Wainwright
8/28/2024	$15.00	Buy	Jefferies
1/3/2024	$4.00 → $8.00	Neutral → Buy	Mizuho
10/26/2023	$57.00 → $4.00	Buy → Neutral	Mizuho
10/13/2023	$32.00 → $6.00	Buy → Neutral	Goldman
9/7/2022	$46.00	Buy	Needham
3/17/2022	$45.00	Buy	Goldman

More analyst ratings

$ARQT
Press Releases

Fastest customizable press release news feed in the world

View All

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeksOnce-daily ZORYVE foam 0.3% is approved to treat seborrheic dermatitis in adults and adolescents 9 years of age and older WESTLAKE VILLAGE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that the American Journal of Clinical Dermatology published data from the Phase 2 long-term safety open-label extension (OLE) study that demonstrated once-daily ZORYVE® (roflumilast) foam 0.3% is safe, well-tolerated,

11/4/25 8:00:00 AM ET

$ARQT

Biotechnology: Pharmaceutical Preparations

Health Care

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

Tori Spelling shares her and her family's journey with eczema and seborrheic dermatitis to encourage others to take control of their skin healthZORYVE® (roflumilast) is the #1 prescribed branded topical therapy for three major inflammatory skin conditions combined – eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the Free to Be Me awareness campaign featuring actress Tori Spelling, and her daughter, Stella (17). The campaign aims to shed light on the em

10/30/25 9:15:00 AM ET

$ARQT

Biotechnology: Pharmaceutical Preparations

Health Care

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05% provides rapid clearance of atopic dermatitisZORYVE can be used anywhere on the body for any duration and is not a steroidAtopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children in the U.S. WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the commercial launch of ZORYVE® (roflumilast) cream 0.05% for the treatment of mild to

10/30/25 8:00:00 AM ET

$ARQT

Biotechnology: Pharmaceutical Preparations

Health Care

$ARQT
Financials

Live finance-specific insights

View All

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and Drug Administration (FDA) approval for the treatment of atopic dermatitis in children down to 2 years of age in October Company provides initial 2026 full year net product sales guidance of $455–$470 million WESTLAKE VILLAGE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today outlined its strategy to achieve sustainable growth and reported

10/28/25 8:30:00 AM ET

$ARQT

Biotechnology: Pharmaceutical Preparations

Health Care

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

Q2 2025 net product revenue for ZORYVE® (roflumilast) was $81.5 million, a 164% increase compared to Q2 of 2024, and a 28% increase compared to Q1 of 2025, driven by strong portfolio demand growthZORYVE foam 0.3% received U.S. Food and Drug Administration (FDA) approval for the treatment of plaque psoriasis of the scalp and body in adults and adolescents 12 years of age and olderInitiated INTEGUMENT-INFANT study to evaluate the safety and efficacy of ZORYVE cream 0.05% in infants with atopic dermatitis ages 3 months to 24 monthsSubmitted Investigational New Drug Application (IND) for ARQ-234, a novel fusion protein for the potential treatment of patients with atopic dermatitis WESTLAKE VI

8/6/25 4:00:00 PM ET

$ARQT

Biotechnology: Pharmaceutical Preparations

Health Care

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

WESTLAKE VILLAGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the call and the presentation materials will be available on the "Events" section of the Company's website. An archived replay of the webcast will be available on the Arcutis investor website following

7/23/25 4:00:00 PM ET

$ARQT

Biotechnology: Pharmaceutical Preparations

Health Care

$ARQT
Leadership Updates

Live Leadership Updates

View All

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration

9/3/25 7:30:00 AM ET

$ARQT

$PVLA

Biotechnology: Pharmaceutical Preparations

Health Care

Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie. "We are t

9/27/23 8:00:00 AM ET

$ARQT

Biotechnology: Pharmaceutical Preparations

Health Care

Arcutis Announces Leadership Transition

Senior Vice President and Chief Commercial Officer (CCO) Ken Lock Stepping DownAyisha Jeter Appointed Interim CCO WESTLAKE VILLAGE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a leadership change. Ken Lock, who has served as Senior Vice President and Chief Commercial Officer (CCO) since October 2019, is stepping down to attend to personal matters effective June 2, 2023. During this transition period, Arcutis' Vice President of Market Access, Ayisha Jeter, has been appointed interim CCO. Mr. Lock's contributions t

5/24/23 5:00:03 PM ET

$ARQT

Biotechnology: Pharmaceutical Preparations

Health Care

FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

Products on NDA 217242

Approval Date(s) and History, Letters, Labels, Reviews for NDA 217242

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $ARQT

FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

Products on NDA 217242

Approval Date(s) and History, Letters, Labels, Reviews for NDA 217242

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $ARQT

$ARQT Insider Purchases

Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

Director Heron Patrick J bought $30,247 worth of shares (2,268 units at $13.34) (SEC Form 4)

Director Heron Patrick J bought $68,821 worth of shares (5,040 units at $13.65) (SEC Form 4)

$ARQT Analyst Ratings

Goldman initiated coverage on Arcutis Biotherapeutics with a new price target

H.C. Wainwright initiated coverage on Arcutis Biotherapeutics with a new price target

Jefferies initiated coverage on Arcutis Biotherapeutics with a new price target

$ARQT Insider Trading

Officer Burnett Patrick sold $156,449 worth of shares (6,486 units at $24.12), decreasing direct ownership by 6% to 98,325 units (SEC Form 4)

Director Welgus Howard G. sold $252,669 worth of shares (10,000 units at $25.27), decreasing direct ownership by 10% to 89,744 units (SEC Form 4)

SVP Chief Financial Officer Vairavan Latha sold $2,175 worth of shares (88 units at $24.72), decreasing direct ownership by 0.14% to 64,927 units (SEC Form 4)

$ARQT Press Releases

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

$ARQT FDA approvals